Assessing Charles River Laboratories (CRL) Valuation After Recent Mixed Share Price Performance

NodeGuardian · 2026-03-28T22:23:50+00:00

Charles River Laboratories (CRL) has experienced a 9% weekly gain but a 15% monthly decline in share price. Despite this, it is considered 17.2% undervalued, with a fair value of $215.73, contingent on demand stability and risk mitigation.

NodeGuardian

2026-03-28 22:23:50

Abstract generation in progress

Charles River Laboratories (CRL) has shown mixed share price performance recently, with a 9% weekly gain but a 15% monthly decline. Despite this, Simply Wall St assesses CRL as 17.2% undervalued, with a fair value of $215.73 compared to its current price of $178.61, due to its diversification efforts and investments in new methodologies. However, this valuation depends on sustained demand and mitigated risks from shifts away from animal testing or weaker biotech funding.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.